Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$3.23 ▲ +0.03
(+0.94%)
MKT CAP: $293.9M • VOL: 458.3K
52W L $2 52W H $5
SABS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $1.3M | $2.2M |
| YoY Revenue Growth % | — | -40.9% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$49.0M | -$42.9M | -$38.1M |
| Operating Margin % | — | -80.0% | -80.0% |
| Net Income (GAAP) | $13.3M | -$34.1M | -$42.2M |
| EBITDA (Normalized) | -$48.2M | -$42.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$44.8M | -$34.3M | -$25.1M |
| Capital Expenditures (CapEx) | $933.2K | $337.3K | — |
| Free Cash Flow (FCF) | -$45.7M | -$34.6M | -$25.1M |
| FCF Margin % | — | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -27.4% | -45.0% | — |
| Cash & Short-Term Equivalents | $10.5M | $8.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $151.5M | $26.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SABS.